LB Pharmaceuticals Inc Common Stock (LBRX)
Stock · NASDAQ · Health Care
$36.74as of 10/16/2026
Price chart
Active signals
LBRX Signal Track Record
How signals performed across all stocks →What LBRX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 3 | +19.9% | 67% | August 6, 2026 |
| Any 20-session window (baseline) | +7.0% | 60% |
Computed by MarketWall from daily closing prices since June 29, 2026. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LBRX
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD;…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 49
- Website
- lbpharma.us/
Fundamentals
- 1-day range
- $34.54$37.43
- Market cap
- $1.38B
- P/E (trailing)
- —
- P/E (forward)
- -7.15
- EPS (trailing)
- $-2.98
- Dividend yield
- —
- Beta
- 1.75
- Avg. volume
- 362.3K
Forecasts
11 analyst ratings
LB Pharmaceuticals Inc Common Stock Competitors
Chosen by industry and closest market cap.
- LBRXLB Pharmaceuticals Inc Common Stock$36.74▲ 0.14%Market cap $1.38BP/E —$14.32$50.16
- ORICOric Pharmaceuticals Inc. Common Stock$12.35▼ 3.29%Market cap $1.34BP/E —$7.23$14.68
- SDGRSchrodinger Inc. Common Stock$22.6▼ 11.30%Market cap $1.33BP/E —$10.95$33.78
- MLTXMoonLake Immunotherapeutics Class A Ordinary Shares$9.55▼ 6.92%Market cap $1.33BP/E —$8.8$23.29
- PAHCPhibro Animal Health Corporation Class A Common Stock$38.82▲ 2.21%Market cap $1.44BP/E 15.44$28.25$60.08
- AVBPArriVent BioPharma Inc. Common Stock$16.66▼ 0.77%Market cap $1.44BP/E —$11.36$35.83
- AKTSAktis Oncology Inc. Common stock$15.06▼ 5.93%Market cap $1.30BP/E —$14.72$34.19
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LBRX LB Pharmaceuticals Inc Common Stock | $1.38B | — | $36.74 | ▲ 0.14% | $14.32$50.16 |
| ORIC Oric Pharmaceuticals Inc. Common Stock | $1.34B | — | $12.35 | ▼ 3.29% | $7.23$14.68 |
| SDGR Schrodinger Inc. Common Stock | $1.33B | — | $22.6 | ▼ 11.30% | $10.95$33.78 |
| MLTX MoonLake Immunotherapeutics Class A Ordinary Shares | $1.33B | — | $9.55 | ▼ 6.92% | $8.8$23.29 |
| PAHC Phibro Animal Health Corporation Class A Common Stock | $1.44B | 15.44 | $38.82 | ▲ 2.21% | $28.25$60.08 |
| AVBP ArriVent BioPharma Inc. Common Stock | $1.44B | — | $16.66 | ▼ 0.77% | $11.36$35.83 |
| AKTS Aktis Oncology Inc. Common stock | $1.30B | — | $15.06 | ▼ 5.93% | $14.72$34.19 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- LB Pharmaceuticals (LBRX) Stock Fair Value Rises As LB 102 Outlook ShiftsYahoo · 10/11/2026
- LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP CongressYahoo · 10/10/2026
- LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/9/2026
- Canaccord Genuity Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $65Benzinga · 10/9/2026
- LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia TreatmentYahoo · 10/6/2026
- Guggenheim Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $80Benzinga · 10/6/2026
- Roth Capital Downgrades LB Pharmaceuticals to Neutral, Lowers Price Target to $35Benzinga · 10/5/2026
- This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Fridaybenzinga · 10/2/2026
- This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayBenzinga · 10/2/2026
Insider Activity
Insider Actions →- Deep Track Biotechnology Master Fund, Ltd. · July 30, 2026 · Buy286.2K @ $34.94
- Luse Rebecca · June 3, 2026 · Grant10.0K
- Robert A. Lenz · June 3, 2026 · Grant12.5K
- Kane William P Jr · June 3, 2026 · Grant10.0K
- Rekha Hemrajani · June 3, 2026 · Grant10.0K
- Ran Nussbaum · June 3, 2026 · Grant10.0K
- Garland J. Scott · June 3, 2026 · Grant10.0K
- RUFFOLO ROBERT R · June 3, 2026 · Grant10.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 26.50M
- Total value held
- $652.03M
- Institutional holders
- 73
- Unknown3.35M
- Unknown2.47M
- Unknown2.21M
- Unknown1.84M
- Unknown1.50M
- Unknown1.44M
- Unknown1.38M
- Unknown1.32M
- Unknown1.05M
- Unknown923.7K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
LBRX News: Fair Value Rises, New Preclinical Data, and Analyst Coverage
LBRX has seen its fair value rise after the company shifted its outlook for LB‑102. The firm also presented new preclinical data supporting the drug’s bimodal mechanism at the ECNP Congress, while continuing late‑stage clinical programs. In addition, Canaccord Genuity added coverage with a price target of $65.
LBRX News: Fair Value Rises, New Preclinical Data, and Analyst Coverage. LBRX has seen its fair value rise after the company shifted its outlook for LB‑102. The firm also presented new preclinical data supporting the drug’s bimodal mechanism at the ECNP Congress, while continuing late‑stage clinical programs. In addition, Canaccord Genuity added coverage with a price target of $65.